Neovasc Inc (US) (NVCN) is Downgraded by Ladenburg Thalmann to Neutral

Neovasc Inc (US) (NVCN) was Downgraded by Ladenburg Thalmann to ” Neutral”. Earlier the firm had a rating of “Buy ” on the company shares. Ladenburg Thalmann advised their investors in a research report released on May 20, 2016.

Neovasc Inc (US) closed down -0.14 points or -7.07% at $1.84 with 11,610 shares getting traded on Thursday. Post opening the session at $2.05, the shares hit an intraday low of $1.785 and an intraday high of $2.05 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

Neovasc Inc. is a specialty medical device company. The Company develops manufactures and markets products for the cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease the Reducer for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. Its Tiara is a product for treating mitral valve disease. The Tiara is in preclinical/early clinical stage development to provide an invasive transcatheter device. The Tiara valve is made up of two components: the leaflets and skirt. It produces Peripatch a biological tissue product that is manufactured from pericardium which is the protective sac that surrounds the heart of an animal. It provides product development and specialized manufacturing services related to Peripatch tissue-based products.

Neovasc Inc (US)

Leave a Reply

Neovasc Inc (US) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neovasc Inc (US). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.